BNF:

CNS

Status:

Grey - after consultant/specialist initiation

Decision Date:

December 2016

Comments

GREY after consultant/specialist initiation and stabilisation: Opicapone is a once daily COMT inhibitor, to be used second-line for patients who are contra-indicated or intolerant to entacapone for Parkinson's Disease. (Decision date - April 2018)

 

Grey Drug Classifications

• 1: Lack of data on effectiveness compared with standard therapy
• 5: Less cost-effective than current standard therapy

search again